Conditions for transient viremia in deterministic in-host models: Viral blips need no exogenous trigger

SIAM Journal on Applied Mathematics

Volumn 73, Issue 2, 2013, Pages 853-881

  Zhang, Wenjing ^a   Wahl, Lindi M ^a   Yu, Pei ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Bifurcation theory; Dynamical system; HIV viral blips; Recurrent infection

Indexed keywords

BIFURCATION THEORY; DETERMINISTIC MODELS; HIV VIRAL BLIPS; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOLOGICAL MODELS; PERSISTENT INFECTION; RECURRENT INFECTION; STOCHASTIC ELEMENTS;

BIFURCATION (MATHEMATICS); DYNAMICAL SYSTEMS; VIRUSES;

STOCHASTIC MODELS;

EID: 84878104817     PISSN: 00361399     EISSN: None     Source Type: Journal    
DOI: 10.1137/120884535     Document Type: Article

References (44)

1. R. M. Anderson and R. M. May, Population biology of infectious diseases: Part I, Nature, 280 (1979), pp. 361-367.
2. R. J. De Boer and A. S. Perelson, Target cell limited and immune control models of HIV infection: A comparison, J. Theoret. Biol., 190 (1998), pp. 201-214.
3. I. Boldogh, T. Albrecht, and D. D. Porter, Persistent viral infections, in Medical Microbiology, University of Texas Medical Branch at Galveston, Galveston, TX, 1996.
4. B. Chan and P. Yu, Bifurcation analysis in a model of cytotoxic T-lymphocyte response to viral infection, Nonlinear Anal., 13 (2012), pp. 64-77.
5. A. C. Collier, R. W. Coombs, D. A. Schoenfeld, R. L. Bassett, J. Timpone, A. Baruch, M. Jones, K. Facey, C. Whitacre, V. J. McAuliffe, H. M. Friedman, T. C. Merigan, R. C. Reichman, C. Hooper, and L. Corey, Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine, New England J. Med., 334 (1996), pp. 1011-1018.
6. J. M. Conway and D. Coombs, A stochastic model of latently infected cell reactivation and viral blip generation in treated HIV patients, PLoS Comput. Biol., 7 (2011), e1002033.
7. S. Devadas, L. Zaritskaya, S. G. Rhee, L. Oberley, and M. S. Williams, Discrete generation of superoxide and hydrogen peroxide by T cell receptor stimulation: Selective regulation of mitogen-activated protein kinase activation and fas ligand expression, J. Exper. Med., 195 (2002), pp. 59-70.
8. G. Dornadula, H. Zhang, B. VanUitert, J. Stern, L. Livornese, Jr., M. J. Ingerman, J. Witek, R. J. Kedanis, J. Natkin, J. DeSimone, and R. J. Pomerantz, Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy, J. Amer. Med. Assoc., 282 (1999), pp. 1627-1632.
9. + T cell and HIV-1 dynamics: Residual viral replication under highly active antiretroviral therapy, Proc. Natl. Acad. Sci. USA, 96 (1999), pp. 15167-15172.
10. C. Fraser, N. M. Ferguson, and R. M. Anderson, Quantification of intrinsic residual viral replication in treated HIV-infected patients, Proc. Natl. Acad. Sci. USA, 98 (2001), pp. 15167-15172.
11. C. Fraser, N. M. Ferguson, F. de Wolf, and R. M. Anderson, The role of antigenic stimulation and cytotoxic T cell activity in regulating the long-term immunopathogenesis of HIV: Mechanisms and clinical implications, Proc. Roy. Soc. B Biol. Sci., 268 (2001), pp. 2085-2095.
12. I. C. H. Fung, M. Gambhir, A. van Sighem, F. de Wolf, and G. P. Garnett, The clinical interpretation of viral blips in HIV patients receiving antiviral treatment: Are we ready to infer poor adherence?, J. Acquired Immune Deficiency Syndromes, 60 (2012), pp. 5-11
13. M. Garland and W. W. Fawzi, Antioxidants and progression of human immunodeficiency virus (HIV) disease, Nutrition Res., 19 (1999), pp. 1259-1276.
14. N. J. Garretta, V. Apeaa, A. Noria, I. Ushiro-Lumbb, A. R. Oliverb, G. Bailya, and D. A. Clarkb, Comparison of the rate and size of HIV-1 viral load blips with Roche COBAS TaqMan HIV-1 versions 1.0 and 2.0 and implications for patient management, J. Clinical Virol., 53 (2012), pp. 354-355.
15. L. Gil, G. Martinez, I. Gonzalez, A. Tarinas, A. Alvarez, A. Giuliani, R. Molina, R. Tapanes, J. Perez, and O. D. Leon, Contribution to characterization of oxidative stress in HIV/AIDS patients, Pharm. Res., 47 (2003), pp. 217-224.
16. G. Gloire, S. Legrand-Poels, and J. Piette, NF-κB activation by reactive oxygen species: Fifteen years later, Biochem. Pharm., 72 (2006), pp. 1493-1505.
17. J. T. Grennan, M. R. Loutfy, D. Su, P. R. Harrigan, C. Cooper, M. Klein, N. Machouf, J. S. G. Montaner, S. Rourke, C. Tsoukas, B. Hogg, J. Raboud, and the CANOC Collaboration, Magnitude of virologic blips is associated with a higher risk for virologic rebound in HIV-infected individuals: A recurrent events analysis, J. Infectious Diseases, 205 (2012), pp. 1230-1238.
18. S. Gropper, J. Smith, and J. Groff, Advanced Nutrition and Human Metabolism, 5th ed., Cengage Learning, Independence, KY, 2009.
19. J. Guckenheimer and P. Holmes, Nonlinear Oscillations, Dynamical Systems, and Bifurcations of Vector Fields, Appl. Math. Sci. 42, Springer-Verlag, New York, 1983.
20. D. A. Hildeman, Regulation of T-cell apoptosis by reactive oxygen species, Free Rad. Biol. Med., 36 (2004), pp. 1496-1504.
21. D. Hinrichsen and A. J. Pritchard, Mathematical Systems Theory I: Modelling, State Space Analysis, Stability and Robustness, 2nd ed., Texts Appl. Math. 48, Springer, New York, 2005.
22. N. Israel and M. A. Gougerot-Pocidalo, Oxidative stress in human immunodeficiency virus infection, Cell. Molec. Life Sciences, 53 (1997), pp. 864-870.
23. L. E. Jones and A. S. Perelson, Opportunistic infection as a cause of transient viremia in chronically infected HIV patients under treatment with HAART, Bull. Math. Biol., 67 (2005), pp. 1227-1251.
24. L. E. Jones and A. S. Perelson, Transient viremia, plasma viral load, and reservoir replenishment in HIV infected patients on antiretroviral therapy, J. Acquired Immune Deficiency Syndromes, 45 (2007), pp. 483-493.
25. H. M. Lander, An essential role for free radicals and derived species in signal transduction, The FASEB J., 11 (1997), pp. 118-124.
26. N. Li and M. Karin, Is nf-κb the sensor of oxidative stress?, The FASEB J., 13 (1999), pp. 1137-1143.
27. M. A. Nowak and C. R. M. Bangham, Population dynamics of immune responses to persistent viruses, Science, 272 (1996), pp. 74-79.
28. M. A. Nowak and R. M. May, Virus Dynamics, Oxford University Press, New York, 2000.
29. G. W. Pace and C. D. Leaf, The role of oxidative stress in HIV disease, Free Rad. Biol. Med., 19 (1995), pp. 523-528.
30. S. Palmer, F. Maldarelli, A. Wiegand, B. Bernstein, G. J. Hanna, S. C. Brun, D. J. Kempf, J. W. Mellors, J. M. Coffin, and M. S. King, Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy, Proc. Natl. Acad. Sci. USA, 105 (2008), pp. 3879-3884.
31. S. Palmer, A. P. Wiegand, F. Maldarelli, H. Bazmi, J. M. Mican, M. Polis, R. L. Dewar, A. Planta, S. Liu, J. A. Metcalf, J. W. Mellors, and J. M. Coffin, New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma, J. Clinical Microbiol., 41 (2003), pp. 4531-4536.
32. A. S. Perelson, P. Essunger, Y. Cao, M. Vesanen, A. Hurley, K. Saksela, M. Markowitz, and D. D. Ho, Decay characteristics of HIV-1-infected compartments during combination therapy, Nature, 387 (1997), pp. 188-191.
33. L. Rong, Z. Feng, and A. Perelson, Mathematical modeling of HIV-1 infection and drug therapy, in Mathematical Modeling of Biosystems, R. P. Mondaini and P. M. Pardalos, eds., Springer-Verlag, New York, 2008, pp. 77-87.
34. L. Rong and A. S. Perelson, Asymmetric division of activated latently infected cells may explain the decay kinetics of the HIV-1 latent reservoir and intermittent viral blips, Math. Biosci., 217 (2009), pp. 77-87.
35. L. Rong and A. S. Perelson, Modeling latently infected cell activation: Viral and latent reservoir persistence, and viral blips in HIV-infected patients on potent therapy, PLoS Comput. Biol., 5 (2009), e1000533.
36. K. B. Schwarz, Oxidative stress during viral infection: A review, Free Rad. Biol. Med., 21 (1996), pp. 641-649.
37. C. B. Stephenson, G. S. Marquis, S. D. Douglas, and C. M. Wilson, Immune activation and oxidative damage in HIV-positive and HIV-negative adolescents, J. Acquired Immune Deficiency Syndromes, 38 (2005), pp. 180-190.
38. C. B. Stephenson, G. S. Marquis, R. A. Jacob, L. A. Kruzich, S. D. Douglas, and C. M. Wilson, Vitamins C and E in adolescents and young adults with HIV infection, Amer. J. Clinical Nutrition, 83 (2006), pp. 870-879.
39. R. D. van Gaalen and L. M. Wahl, Reconciling conflicting clinical studies of antioxidant supplementation as HIV therapy: A mathematical approach, BMC Public Health, 9 (Suppl. 1) (2009), pp. 1-18.
40. L. P. Villarreal, V. R. Defilippis, and K. A. Gottlieb, Acute and persistent viral life strategies and their relationship to emerging diseases, Virology, 272 (2000), pp. 1-6.
41. W. Yao, L. Hertel, and L. M. Wahl, Dynamics of recurrent viral infection, Proc. Roy. Soc. Biol. Sci., 273 (2006), pp. 2193-2199.
42. P. Yu, Computation of normal forms via a perturbation technique, J. Sound Vibration, 211 (1998), pp. 19-38.
43. P. Yu, Closed-form conditions of bifurcation points for general differential equations, Internat. J. Bifur. Chaos Appl. Sci. Engrg., 15 (2005), pp. 1467-1483.
44. P. Yu and K. Huseyin, A perturbation analysis of interactive static and dynamic bifurcations, IEEE Trans. Automat. Control, 33 (1988), pp. 28-41.